1. Home
  2. Analysis
  3. Cellcept
  4. Tamiflu

Cellcept and Tamiflu drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cellcept and Tamiflu. Common interactions include lymphoma among females and anaphylactic shock among males.

The phase IV clinical study analyzes what interactions people who take Cellcept and Tamiflu have. It is created by eHealthMe based on reports of 81 people who take Cellcept and Tamiflu from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 06, 2023

81 people who take Cellcept and Tamiflu together, and have interactions are studied.

What is Cellcept?

Cellcept has active ingredients of mycophenolate mofetil. It is often used in systemic lupus erythematosus. eHealthMe is studying from 37,825 Cellcept users for its effectiveness, alternative drugs and more.

What is Tamiflu?

Tamiflu has active ingredients of oseltamivir phosphate. It is often used in the flu. eHealthMe is studying from 21,206 Tamiflu users for its effectiveness, alternative drugs and more.

Number of Cellcept and Tamiflu reports submitted per year:

Cellcept and Tamiflu drug interactions.

Common Cellcept and Tamiflu drug interactions by gender *:

female:

  1. Lymphoma
  2. Malaise
  3. Pain in extremity
  4. Peripheral swelling
  5. Snake bite
  6. Bronchitis
  7. Conjunctivitis allergic
  8. Gingivitis
  9. Insomnia
  10. Iron deficiency anaemia

male:

  1. Anaphylactic shock
  2. Coronary artery disease
  3. Leukopenia
  4. Lymphoma
  5. Malaise
  6. Pain in extremity
  7. Snake bite
  8. Dyspnoea
  9. Blood cholesterol increased
  10. Diabetes mellitus

Common Cellcept and Tamiflu drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Lung infection
  2. Pathogen resistance
  3. Renal impairment
  4. Headache
  5. Infection
  6. Pyrexia

20-29:

  1. Gastroenteritis
  2. Rhinitis allergic
  3. Nasopharyngitis
  4. Bronchitis
  5. Conjunctivitis allergic
  6. Gingivitis
  7. Insomnia
  8. Iron deficiency anaemia
  9. Mania
  10. Pulmonary hypertension

30-39:

  1. Pneumonia
  2. Agranulocytosis
  3. Abdominal pain
  4. Abortion induced
  5. Bacteraemia
  6. Burkholderia cepacia complex infection
  7. Cholecystitis
  8. Death
  9. Dyspnoea
  10. Graft versus host disease

40-49:

  1. Shock
  2. Depressed level of consciousness
  3. Sinus tachycardia
  4. White blood cell count decreased
  5. Altered state of consciousness
  6. Blood creatinine increased
  7. Blood urea increased
  8. Chronic kidney disease
  9. Gastrointestinal haemorrhage
  10. Influenza a virus test positive

50-59:

  1. Anaphylactic shock
  2. Coronary artery disease
  3. Cytomegalovirus infection
  4. Epstein-barr virus infection
  5. Erythema
  6. Excessive granulation tissue
  7. Feeling hot
  8. Heart transplant rejection
  9. Immunosuppressant drug level decreased
  10. Interleukin-2 receptor increased

60+:

  1. Renal failure
  2. Chronic kidney disease
  3. Bronchitis
  4. Confusional state
  5. Constipation
  6. Cystitis
  7. Diabetic neuropathy
  8. Eczema
  9. Enterocolitis
  10. Glucose tolerance impaired

Common conditions people have *:

  1. High Blood Cholesterol: 17 people, 20.99%
  2. High Blood Pressure: 17 people, 20.99%
  3. Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 14 people, 17.28%
  4. Hyperlipidaemia (presence of excess lipids in the blood): 12 people, 14.81%
  5. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 10 people, 12.35%
  6. Gastroenteritis (inflammation of stomach and intestine): 10 people, 12.35%
  7. Pain: 10 people, 12.35%
  8. Back Pain: 9 people, 11.11%
  9. Nasopharyngitis (inflammation of the nasopharynx): 9 people, 11.11%
  10. Conjunctivitis Allergic (inflammation of the conjunctiva due to allergy): 7 people, 8.64%

* Approximation only. Some reports may have incomplete information.

Do you take Cellcept and Tamiflu?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Common Cellcept and Tamiflu interactions:

Browse all drug interactions of Cellcept and Tamiflu:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cellcept side effects:

Browse all side effects of Cellcept:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tamiflu side effects:

Browse all side effects of Tamiflu:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cellcept interactions:

Browse all interactions between Cellcept and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tamiflu interactions:

Browse all interactions between Tamiflu and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil and oseltamivir phosphate (the active ingredients of Cellcept and Tamiflu, respectively), and Cellcept and Tamiflu (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Cellcept and Tamiflu.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.